Gainers
- Femasys FEMY shares moved upwards by 56.8% to $0.52 during Monday's after-market session. This security traded at a volume of 461.0K shares come close, making up 12.7% of its average volume over the last 100 days. The company's market cap stands at $7.8 million.
- Pliant Therapeutics PLRX stock rose 15.85% to $16.89. The company's market cap stands at $1.0 billion.
- Ontrak OTRK stock moved upwards by 10.45% to $0.95. The company's market cap stands at $4.6 million.
- Brainstorm Cell BCLI stock moved upwards by 9.42% to $0.47. This security traded at a volume of 566.4K shares come close, making up 202.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $21.0 million.
- 180 Life Sciences ATNF shares moved upwards by 8.65% to $0.65. The company's market cap stands at $3.8 million.
- Matinas BioPharma Hldgs MTNB stock moved upwards by 7.84% to $0.13. The company's market cap stands at $29.2 million.
Losers
- TransCode Therapeutics RNAZ stock declined by 20.0% to $2.04 during Monday's after-market session. This security traded at a volume of 15.7 million shares come close, making up 2625.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $4.1 million.
- Biophytis BPTS stock fell 8.18% to $1.46. At the close, Biophytis's trading volume reached 6.6 million shares. This is 1490.8% of its average volume over the last 100 days. The company's market cap stands at $7.8 million.
- NeuBase Therapeutics NBSE stock decreased by 7.69% to $0.79. The market value of their outstanding shares is at $2.9 million.
- Tivic Health Systems TIVC stock fell 5.48% to $1.9. The company's market cap stands at $2.7 million.
- Immix Biopharma IMMX stock decreased by 5.44% to $2.8. The company's market cap stands at $45.5 million.
- Inozyme Pharma INZY shares decreased by 4.88% to $4.1. The company's market cap stands at $253.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in